Medicenna Therapeutics Corp. (MDNA.TO) Investment Analysis:

1. Executive Summary:

Medicenna Therapeutics Corp. (TSX: MDNA; OTCQX: MDNAF) stands at a critical juncture in the evolution of immuno-oncology, operating as a clinical-stage biotechnology company focused on the development of "Superkines"—highly selective, engineered versions of naturally occurring interleukins (IL-2, IL-4, and IL-13). The company's investment thesis is currently defined by a profound dislocation between its intrinsic scientific value, validated by recent clinical data and institutional backing, and its distressed market valuation. As of late 2025, Medicenna is transitioning from a speculative development platform into a clinically validated entity with a potentially best-in-class asset, MDNA11, targeting the vast market of checkpoint-inhibitor-resistant solid tumors.

The core of Medicenna’s value proposition addresses one of the most persistent challenges in cancer immunotherapy: the "Cytokine Paradox." Naturally occurring cytokines like Interleukin-2 (IL-2) are among the most potent immune stimulators known to science, capable of inducing durable cures in advanced cancer. However, their therapeutic utility has historically been severely limited by life-threatening toxicities—specifically Vascular Leak Syndrome (VLS)—and counter-productive immunosuppression caused by the stimulation of Regulatory T cells (Tregs) via the alpha receptor (CD25). Medicenna’s proprietary Directed Evolution platform has generated MDNA11, an IL-2 agonist engineered to have zero affinity for CD25 and enhanced affinity for the beta receptor (CD122), theoretically and now clinically decoupling efficacy from toxicity.

The company operates in three distinct, high-value market segments:

1. The IL-2 Renaissance (Solid Tumors): This is the primary value driver. The market for next-generation IL-2 therapies is driven by the urgent need to improve outcomes for the ~70-80% of patients who do not respond to or progress on checkpoint inhibitors (PD-1/L1 blockade). MDNA11 is positioning itself as the ideal combination partner to "heat up" these cold tumors, with recent Phase 1/2 data demonstrating objective responses in patients refractory to standard-of-care immunotherapy.

2. Neuro-Oncology (Recurrent Glioblastoma): Targeted by the Phase 3-ready asset bizaxofusp (MDNA55), this segment represents a significant unmet medical need with no curative standard of care. Glioblastoma (GBM) remains uniformly fatal, and MDNA55 leverages an IL-4 receptor-targeted payload delivered directly to the brain, bypassing the blood-brain barrier constraints that doom most systemic therapies.

3. Next-Generation Bispecifics: The nascent MDNA113 program targets the convergence of cytokine therapy and checkpoint inhibition in a single molecule, addressing a rapidly growing sub-segment of the immunotherapy market expected to dominate clinical pipelines in the late 2020s.

In 2024 and 2025, Medicenna significantly de-risked its platform through the "ABILITY-1" clinical trial, reporting deep and durable responses in difficult-to-treat cancers such as pancreatic cancer and melanoma. Furthermore, the company secured a CA$20 million strategic investment from RA Capital Management in April 2024, a tier-1 life sciences investor, which provided not only capital but critical external validation of the science. Despite these fundamentals, the company trades at a fraction of the valuations commanded by comparable IL-2 peers acquired during the 2019-2021 biotech boom (e.g., Synthorx, Pandion).

The central tension for investors is the timeline to monetization versus the "mid-2026" cash runway. This report posits that the market is mispricing the probability of a strategic transaction or partnership, offering an asymmetric risk-reward profile for investors willing to tolerate the binary risks inherent in small-cap biotech.

2. Business Drivers & Strategic Overview:

The strategic engine of Medicenna Therapeutics is its proprietary Directed Evolution platform, which allows for the fine-tuning of cytokine receptor binding affinities. This technological capability drives three distinct revenue and value creation streams, each at a different stage of maturity and risk profile.

Driver 1: MDNA11 – The Long-Acting IL-2 Superkine (The Value Anchor)

MDNA11 is the company’s primary valuation driver in the current fiscal environment. It is an engineered IL-2 super-agonist fused to human albumin for extended half-life.

The Scientific Moat: Beta-Enhanced, Not-Alpha

To understand the driver, one must understand the failure of the competition. The first generation of IL-2 (Proleukin) failed to achieve widespread use because it bound indiscriminately to all IL-2 receptors. Most importantly, it bound to CD25 (the alpha receptor) on endothelial cells, causing fluid to leak into the lungs (VLS), and on Tregs, which shut down the immune attack on the tumor. Competitors like Nektar Therapeutics attempted to solve this by "masking" the IL-2 with PEG chains (PEGylation). This approach failed in Phase 3 because the mask eventually fell off in the body, revealing the native IL-2 which then stimulated CD25. Medicenna’s approach is fundamentally different. They did not just mask the molecule; they re-engineered the protein itself. MDNA11 has specific mutations (F42A and E62A) that biologically ablate binding to CD25. It physically cannot stimulate the alpha receptor, regardless of whether it is masked or not. Furthermore, it has mutations (L80F, R81D, L85V, I86V, I92F) that increase binding to CD122 by 30-fold. This "Beta-only" signaling profile is designed to preferentially stimulate cancer-killing CD8+ T cells and Natural Killer (NK) cells. This structural differentiation is Medicenna's key competitive moat.

Clinical Validation (ABILITY-1 Study)

The ABILITY-1 study is the crucible in which this hypothesis is being tested. As of the December 2025 data cut-off presented at ESMO-IO, MDNA11 is generating data that separates it from the "graveyard" of failed IL-2 assets.

• Efficacy in Resistant Patients: The study reported an Objective Response Rate (ORR) of 42% (5 of 12) and a Disease Control Rate (DCR) of 83% in patients treated with MDNA11 after progressing on a checkpoint inhibitor. This is the critical "prove it" metric. Patients who fail PD-1 inhibitors typically have response rates of 5-10% with standard chemotherapy. Achieving 42% in this population suggests MDNA11 is actively reversing resistance.

• Tumor Specificity:

  • Microsatellite Stable (MSS) Endometrial Cancer: Historically a "cold" tumor unresponsive to immunotherapy. MDNA11 achieved a 50% ORR (2 of 4).

  • Cutaneous Melanoma: In patients with secondary resistance to checkpoint inhibitors, the ORR was 38%.

• Durability and "Memory": A pancreatic cancer patient (MSI-H) achieved a durable response lasting over 21 months off-treatment. Pancreatic cancer is notoriously aggressive; seeing a two-year remission in a refractory patient is clinically exceptional and points to the induction of immunological memory.

• Safety Profile: Unlike Proleukin, MDNA11 has shown no Dose Limiting Toxicities (DLTs) at doses up to 120 µg/kg, with over 90% of adverse events being low-grade (Grade 1-2) and transient. This safety profile allows for convenient outpatient dosing, a prerequisite for mass commercial adoption.

Growth Initiative: Accelerated Approval

The immediate growth strategy involves finalizing the Phase 2b development plan by the end of calendar 2025. Management has indicated they are targeting an "accelerated approval" pathway. By focusing on specific high-response indications—likely MSI-H tumors or refractory melanoma—Medicenna aims to run a smaller, single-arm registrational trial rather than a massive, multi-year randomized Phase 3. This strategy drastically reduces the capital requirements and time to market.

Driver 2: MDNA55 (Bizaxofusp) – The Commercial-Ready Asset

While MDNA11 drives the hype, MDNA55 represents the tangible asset value. It is an IL-4 targeted toxin designed for Recurrent Glioblastoma (rGBM).

The Unmet Need

GBM is the most aggressive form of brain cancer. Even with surgery, radiation, and chemotherapy, recurrence is inevitable. Once it recurs, median overall survival (mOS) is 6-9 months. There has been no significant drug approval in this space for decades.

Mechanism and Delivery

MDNA55 uses IL-4 as a "Trojan Horse." GBM cells massively overexpress the IL-4 receptor (IL-4R), whereas healthy brain tissue does not. MDNA55 binds to these receptors and is internalized, releasing a potent bacterial toxin that kills the cell. Because the blood-brain barrier blocks most drugs, MDNA55 is delivered directly into the tumor via Convection Enhanced Delivery (CED)—a surgical procedure that pumps the drug through catheters.

Regulatory Status: The Hybrid Control

The asset has completed Phase 2b and has a creatively de-risked path to approval. The FDA has agreed to a "hybrid control" design for the Phase 3 LIGHT trial.

• The Design: Instead of randomizing hundreds of patients to a control arm (standard chemotherapy), Medicenna can use matched external controls (historical patient data) for two-thirds of the control arm.

• The Implication: This reduces the number of patients needed for the trial by roughly 100-150 patients. In oncology trials, where per-patient costs can exceed $100,000, this saves $10-$15 million and cuts enrollment time by 12-18 months.

Partnership Dynamics

Medicenna is "actively pursuing" a partner to fund this trial. The delay in securing a partner has been a drag on the stock. However, with the Phase 3 design locked in and Orphan Drug status granted , the asset remains a prime candidate for a specialty oncology company looking for a near-commercial asset. A partnership deal here is the most likely source of non-dilutive capital in the "Base Case" scenario.

Driver 3: The BiSKITs Platform (MDNA113)

Looking beyond 2025, the Bifunctional SuperKine ImmunoTherapies (BiSKITs) platform drives long-term value.

• The Logic of Bispecifics: Currently, combination therapy (e.g., Anti-PD1 + IL-2) requires two separate infusions, two separate manufacturing costs, and two separate safety profiles. MDNA113 fuses the anti-PD1 mechanism with the IL-2 superkine into a single molecule.

• Differentiation: It is designed to be "tumor-anchored" and "masked." The IL-2 payload is inactive until it reaches the tumor, where proteases (enzymes abundant in tumors) cleave the mask, activating the cytokine. This ensures the potent immune stimulation happens only at the tumor site, further improving the safety window.

• Timeline: IND-enabling studies are complete, with Phase 1 initiation slated for 2026. This puts Medicenna in the race with major players like Roche and Xilio who are also exploring tumor-activated cytokines.

Competitive Advantages Summary

1. Receptor Selectivity: The ability to engineer "Superkines" with specific binding affinities (e.g., zero CD25 binding) is a hard-science barrier to entry that separates MDNA from "masking-only" competitors like Nektar.

2. Clinical Validation: While many IL-2 competitors have failed in late-stage trials due to lack of efficacy or toxicity, MDNA11 is generating confirmed responses in monotherapy, proving the molecule works on its own—a rarity in this space.

3. Intellectual Property: The company secured six new patents in late 2025 across the US, Japan, and Canada, protecting the Superkine and BiSKITs platforms. This expands the "exclusivity runway," ensuring that if MDNA11 is approved, it will enjoy a long lifecycle before generic competition.

3. Financial Performance & Valuation:

As of late December 2025, Medicenna’s financial profile reflects that of a classic pre-revenue development-stage biotech: high cash burn, reliance on equity financing, and a valuation driven by clinical milestones rather than earnings. However, a deeper look reveals a balance sheet that has been strategically fortified to weather the near-term storm.

Recent Historical Performance (Fiscal 2024-2026)

The fiscal year (FY) for Medicenna ends on March 31. The analysis below synthesizes data from FY2024 through the most recent quarter (Q2 Fiscal 2026, ended September 30, 2025).

Cash Position & Liquidity Analysis

• Trajectory:

  • FY 2024 End (March 31, 2024): Cash and equivalents were $17.0 million.

  • FY 2025 End (March 31, 2025): Cash decreased as the ABILITY-1 trial ramped up.

  • Q2 Fiscal 2026 (Sept 30, 2025): Cash and equivalents stood at $30.0 million. This crucial increase was not organic but driven by the RA Capital financing and warrant exercises.

• Burn Rate: For the fiscal year ended March 31, 2024, total operating costs were $18.7 million. The net loss for the quarter ended September 30, 2024 (Q2 Fiscal 2025), was $4.2 million. Projecting this forward, the company has a quarterly burn rate of approximately $4.0 - $4.5 million. This is relatively lean for a company running a global Phase 1/2 trial, reflecting disciplined capital allocation.

• Runway Guidance: Management explicitly states the current cash balance provides a runway through "mid-calendar year 2026". This is the single most important timeline for investors. It implies the company has approximately 6-8 months (from December 2025) to generate a catalyst that enables a capital raise or partnership.

Financing Activities & Cap Table Structure

• RA Capital Investment (The Validator): In April 2024, RA Capital invested CA$20millionviaaprivateplacementatCA$1.95 per share.

  • Significance: RA Capital is a sophisticated, specialized biotech investor. Their willingness to invest at CA$1.95—nearlydoublethesharepriceofCA$1.02 in December 2025—signals their internal valuation models see significantly higher intrinsic value.

  • Structure: They purchased 5,141,388 common shares and pre-funded warrants. This structure allows them to hold a large economic interest without triggering "change of control" ownership thresholds.

• Warrant Overhang & Exercises: In late 2025, the company received proceeds of $3.8 million from the exercise of roughly 2.5 million warrants.

  • Outstanding Warrants: There are still significant warrants outstanding. For example, 1.5 million warrants had their expiry extended to October 2024 (past date, likely exercised or expired). As of mid-2025, RA Capital holds pre-funded warrants. The exercise of these warrants acts as a double-edged sword: it provides cash but caps the share price upside as warrant holders sell shares to lock in profits.

Valuation Metrics & Multiples

As of December 20, 2025, with the stock trading near CA$1.02 , the valuation presents a stark disconnect from the sum-of-the-parts analysis.

• Market Capitalization: Approximately CA$85million(approx.US$60 million) based on ~83 million shares outstanding.

• Enterprise Value (EV): With ~$30MCADincashandnosignificantdebt,theEVisapproximatelyCA$55 million (US$40 million).

• Relative Valuation (Comparable Transactions): To understand the mispricing, we must look at what Big Pharma pays for similar IL-2 assets.

  • Synthorx (Sanofi Acquisition, 2019): Acquired for $2.5 billion. Their asset, THOR-707, was a pegylated IL-2. MDNA11 has shown superior receptor selectivity in preclinical models compared to the Synthorx approach.

  • Pandion Therapeutics (Merck Acquisition, 2021): Acquired for $1.85 billion. Their lead asset was an IL-2 mutein for autoimmune disease. This validates that engineered IL-2 biology commands billion-dollar premiums.

  • Good Therapeutics (Roche Acquisition, 2022): Acquired for $250 million upfront (plus milestones) for a preclinical PD-1-regulated IL-2 asset. This is a direct comparable to MDNA113 (BiSKITs). The fact that MDNA's entire EV is $40M while a preclinical competitor sold for $250M highlights the disconnect.

  • Xilio Therapeutics (Gilead Deal, 2024): Gilead paid $43.5 million upfront (plus $600M milestones) for an exclusive license to a Phase 1 tumor-activated IL-12 program. This sets a "floor" value for a Phase 1 cytokine asset at roughly the current entire Enterprise Value of Medicenna.

Valuation Conclusion: Medicenna is currently trading at a negative enterprise value relative to the intrinsic value of a clinically validated IL-2 asset. The market is effectively assigning a near-zero value to MDNA55 and pricing MDNA11 at a fraction of the value of comparable assets. The valuation is compressed by the "mid-2026" financing overhang and the general bearish sentiment in the microcap biotech sector.

4. Risk Assessment & Macroeconomic Considerations:

Major Risks

1. Financing and Dilution Risk (High): This is the immediate existential threat. With cash runway only until mid-2026 , Medicenna must raise capital within the next 3-6 months.

   • Impact: If they cannot secure a non-dilutive partnership, they will be forced to issue equity. At CA$1.02,raisingCA$20M would dilute shareholders by ~20-25%. If the stock drops further, a "death spiral" financing could occur.

   • Mitigant: The high insider ownership (Merchants ~20%) and RA Capital backing provides some defense against predatory financing.

2. Competitive Landscape Risk (Medium-High): The IL-2 space is crowded ("The Cytokine Zoo").

   • Competitors: Anaveon (ANV419), Cue Biopharma (CUE-101), and Synthekine (STK-012) are all advancing IL-2 variants.

   • Sector Stigma: High-profile failures, specifically the BMS/Nektar bempegaldesleukin failure in melanoma, cast a long shadow. Investors are skeptical of IL-2. Medicenna bears the burden of proof to show "this time is different."

3. Clinical Development Risk (Medium):

   • Combination Efficacy: While monotherapy data is strong, the commercial market is in combination with checkpoint inhibitors. The data with Keytruda needs to be statistically unequivocal.

   • Regulatory Hurdles: The FDA's "Project Optimus" is adding scrutiny to dose optimization in early-phase oncology. While MDNA has done this work, any FDA request for more dose-finding cohorts would delay Phase 3 and burn critical cash.

4. Partnership Execution Risk (Medium):

   • MDNA55 Stagnation: The company has been "actively pursuing" a partnership for MDNA55 for years. The inability to close a deal suggests potential partner concerns—likely regarding the complexity of CED delivery (needing neurosurgeons) or the small size of the rGBM market. If this asset cannot be monetized, it generates zero value.

Macroeconomic Considerations

• Interest Rate Environment: In late 2025, the cost of capital remains a significant factor. High interest rates punish long-duration assets like biotechs. Generalist investors have fled the sector, leaving only specialists like RA Capital. This lack of liquidity makes retail-driven rallies harder to sustain.

• M&A Cycle: Conversely, the macro environment favors M&A. Big Pharma faces patent cliffs (e.g., Keytruda LOE in 2028) and has accumulated cash. They need to buy growth. The "buy vs. build" calculus favors acquiring de-risked assets like MDNA11. 2024/2025 saw a resurgence in licensing deals and M&A for immunology assets. This trend supports the "High Case" scenario.

• China Biopharma Factor: Western pharma is increasingly licensing assets from China. This creates price competition for assets. However, geopolitical tensions may make Western-originated assets (like MDNA's) more attractive for US-based acquirers due to supply chain security (the Biosecure Act implications).

5. 5-Year Scenario Analysis:

Context: This analysis projects outcomes to December 2030 based on the status as of December 2025. The share price inputs assume a current trading price of ~CA$1.02 and ~85M shares outstanding. Fully diluted share count is estimated at ~100M (including RA Capital warrants and options).

Scenario 1: High Case – "The Unicorn Acquisition"

• Narrative: MDNA11 is definitively proven as the "best-in-class" IL-2.

  • Fundamentals: Throughout 2026, the ABILITY-1 expansion cohorts show sustained ORRs >35% in checkpoint-refractory melanoma and MSI-H tumors. The FDA grants "Breakthrough Therapy Designation."

  • The Catalyst: A major checkpoint inhibitor manufacturer (Merck, BMS, or Roche) realizes they need a proprietary IL-2 to extend the life of their franchise (Keytruda/Opdivo). A bidding war ensues.

  • MDNA55 Contribution: Simultaneously, MDNA55 is licensed to a mid-sized partner for $50M upfront + royalties, removing the cash burn overhang and allowing the company to negotiate the acquisition from a position of strength.

• Valuation Logic (Provenance):

  • Comparable: Synthorx ($2.5B acquisition by Sanofi). Pandion ($1.85B by Merck).

  • Adjustment: Given MDNA11 is in Phase 2 (more advanced than Synthorx was), but market multiples are lower than 2019, we apply a conservative acquisition value of US$1.5 Billion (CA$2.1 Billion).

  • Dilution: Assumes minimal dilution before acquisition (100M shares).

• Projected Share Price: CA$2,100M/100Mshares=\ast \ast CA$21.00.

• Probability: 20%

Scenario 2: Base Case – "Strategic Partnership & Commercialization"

• Narrative: Medicenna remains independent but partners its assets.

  • Fundamentals: In mid-2026, Medicenna signs a global collaboration deal for MDNA11 with a Tier-1 pharma.

  • Deal Terms (Provenance): Based on the Xilio/Gilead deal ($43M upfront) and Synthekine/Sanofi deal ($40M upfront) , but scaled for Phase 2 data. We assume $100M Upfront, $1B in milestones, and 15% royalties.

  • Financial Impact: The $100M upfront creates a cash runway to 2029. MDNA11 enters Phase 3. MDNA55 enters Phase 3 funded by a regional partner (e.g., Asia rights).

  • Valuation Method: Risk-Adjusted NPV (rNPV).

    • MDNA11 rNPV: $1.5B peak sales 3x multiple 40% probability of success = $1.8B unadjusted -> Risk adjusted ~$400M.

    • MDNA55 rNPV: $500M peak sales 2x multiple 60% probability = $600M -> Risk adjusted ~$100M.

    • Cash: $150M.

    • Total EV: CA$650M.

• Projected Share Price: CA$650M/110Mshares(assumingslightdilution)=\ast \ast CA$5.90.

• Probability: 50%

Scenario 3: Low Case – "Dilution Spiral & Niche Survival"

• Narrative: The "funding cliff" bites.

  • Fundamentals: No partnership materializes by mid-2026. The company is forced to execute a highly dilutive financing in a weak market (e.g., at CA$0.75 or lower with full warrant coverage) to survive.

  • Clinical: MDNA11 shows efficacy but fails to significantly outperform competitors in the larger Phase 2b cohorts, making it a "me-too" drug. MDNA55 remains shelved.

  • Outcome: The company survives as a small-cap zombie, funding small trials and hoping for a buyout.

• Valuation Logic: Valuation reverts to cash value plus a minimal technology premium.

• Projected Share Price: Market Cap CA$50M/150Mshares(heavydilution)=\ast \ast CA$0.33.

• Probability: 30%

Share Price Trajectory Table (CAD)

Probability Weighted Price Target (5-Year): ($21.00 0.20) + ($5.90 0.50) + ($0.33\ast 0.30)=\ast \ast CA$7.25

Summary: ASYMMETRIC UPSIDE POTENTIAL

6. Qualitative Scorecard:

Overall Blended Score: 6.5/10

Summary: SCIENTIFICALLY ROBUST, FINANCIALLY FRAGILE

7. Conclusion & Investment Thesis:

Medicenna Therapeutics represents a classic "high-risk, high-reward" deep value opportunity in the biotech sector. The market is currently pricing MDNA as if its assets have failed or possess negligible value, despite the ABILITY-1 trial delivering objective response rates (42% in refractory patients) that rival or exceed those of blockbuster immunotherapies. The disconnect between the Enterprise Value (~US$40M) and the strategic value of a validated, toxicity-reduced IL-2 agonist (historically >$1B) is extreme and unsustainable.

The investment thesis relies on the "Beta-enhanced" hypothesis being proven correct—which the clinical data now supports. The MDNA11 molecule successfully decouples efficacy from the notorious toxicity of IL-2. With RA Capital providing institutional floor support and a cash runway extending to mid-2026, Medicenna has a 6-month window to execute a transformational partnership or sale.

Key Catalysts to Watch:

1. Partnership for MDNA55: Any monetization of this asset is pure upside and resolves the cash crunch.

2. Phase 2b Design Finalization (Q1 2026): Clarifying the registrational path (e.g., accelerated approval via a single-arm trial) will allow the market to model a concrete timeline to revenue.

3. MDNA113 IND Filing (2026): Entry of the bispecific into the clinic adds a new "leg" to the valuation stool, drawing comparisons to Roche's pipeline.

Summary: DEEP VALUE ASYMMETRY

8. Technical Analysis, Price Action & Short-Term Outlook:

As of Dec 20, 2025, MDNA.TO is trading at ~CA$\mathrm{1.02.}Thestockistechnicallybearish,tradingbelowits50-day(CA$1.18) and 200-day (CA$1.42) moving averages, confirming a medium-term downtrend. However, the RSI (14) is neutral-to-oversold, and the price is consolidating near historical support levels of $0.96-$1.00. The "Death Cross" (50 DMA crossing below 200 DMA) signals caution, but recent volume accumulation suggests smart money may be positioning for a reversal pending early 2026 catalysts. A break above $1.08 is needed to signal a trend change.

Summary: OVERSOLD CONSOLIDATION ZONE